Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a multi-centre, double-blind, randomized phase III trial comparing metformin to
placebo in patients with advanced prostate cancer starting androgen deprivation therapy.
Phase:
Phase 3
Details
Lead Sponsor:
British Columbia Cancer Agency Canadian Urologic Oncology Group
Collaborators:
British Columbia Cancer Agency Canadian Urologic Oncology Group Prostate Cancer Canada